Tanvex BioPharma (TPE:6541) Cyclically Adjusted Book per Share: NT$32.10 (As of Dec. 2025)


TPE:6541 Tanvex BioPharma Inc TPE:6541
57 GF Score
Price NT$41.40
GF Value NT$254.61
Valuation Possible Value Trap
! 4 Warning Signs
View Full Analysis

What is Tanvex BioPharma Cyclically Adjusted Book per Share?

Tanvex BioPharma TPE:6541 +2.10% 57 Cyclically Adjusted Book per Share is NT$32.10 as of Dec. 2025. GuruFocus rates TPE:6541 with a GF Score™ of 57/100 and a GF Value™ of NT$254.61 (Possible Value Trap). The stock has 4 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Tanvex BioPharma's adjusted book value per share for the three months ended in Dec. 2025 was NT$21.498. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is NT$32.10 for the trailing ten years ended in Dec. 2025.

During the past 12 months, Tanvex BioPharma's average Cyclically Adjusted Book Growth Rate was 2.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

As of today (2026-07-05), Tanvex BioPharma's current stock price is NT$41.40. Tanvex BioPharma's Cyclically Adjusted Book per Share for the quarter that ended in Dec. 2025 was NT$32.10. Tanvex BioPharma's Cyclically Adjusted PB Ratio of today is 1.29.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Tanvex BioPharma was 2.47. The lowest was 1.19. And the median was 1.64.


Tanvex BioPharma  (TPE:6541) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Tanvex BioPharma's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=41.40/32.10
=1.29

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Tanvex BioPharma was 2.47. The lowest was 1.19. And the median was 1.64.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Tanvex BioPharma Cyclically Adjusted Book per Share Related Terms


Tanvex BioPharma Cyclically Adjusted Book per Share Historical Data

* Premium members only.

The historical data trend for Tanvex BioPharma's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Tanvex BioPharma Cyclically Adjusted Book per Share Chart

Tanvex BioPharma Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 31.37 32.10

Tanvex BioPharma Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 31.37 32.16 32.64 32.43 32.10

TPE:6541 vs VRTX, REGN, ALNY: Cyclically Adjusted Book per Share Comparison

For the Biotechnology subindustry, Tanvex BioPharma's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Tanvex BioPharma Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Tanvex BioPharma's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Tanvex BioPharma's Cyclically Adjusted PB Ratio falls into.


TPE:6541
57GF Score
Tanvex BioPharma Inc TPE:6541
Cyclically Adjusted Book per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Tanvex BioPharma Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Tanvex BioPharma's adjusted Book Value per Share data for the three months ended in Dec. 2025 was:

Adj_Book= Book Value per Share /CPI of Dec. 2025 (Change)*Current CPI (Dec. 2025)
=21.498/324.0540*324.0540
=21.498

Current CPI (Dec. 2025) = 324.0540.

Tanvex BioPharma Quarterly Data

Book Value per Share CPI Adj_Book
201603 0.000 238.132 0.000
201606 60.622 241.018 81.508
201609 0.000 241.428 0.000
201612 51.064 241.432 68.539
201703 44.042 243.801 58.539
201706 39.770 244.955 52.612
201709 35.893 246.819 47.125
201712 47.733 246.524 62.745
201803 43.177 249.554 56.067
201806 37.422 251.989 48.124
201809 52.944 252.439 67.964
201812 48.262 251.233 62.251
201903 43.016 254.202 54.836
201906 37.649 256.143 47.631
201909 30.461 256.759 38.445
201912 32.139 256.974 40.529
202003 26.126 258.115 32.800
202006 19.675 257.797 24.732
202009 15.039 260.280 18.724
202012 24.049 260.474 29.919
202103 20.619 264.877 25.226
202106 16.904 271.696 20.162
202109 25.659 274.310 30.312
202112 22.886 278.802 26.601
202203 20.404 287.504 22.998
202206 17.720 296.311 19.379
202209 15.452 296.808 16.870
202212 11.388 296.797 12.434
202303 8.338 301.836 8.952
202306 13.160 305.109 13.977
202309 10.060 307.789 10.592
202312 6.021 306.746 6.361
202403 3.004 312.332 3.117
202406 8.935 314.175 9.216
202409 6.941 315.301 7.134
202412 5.400 315.605 5.545
202503 23.065 319.799 23.372
202506 20.253 322.561 20.347
202509 22.663 324.800 22.611
202512 21.498 324.054 21.498

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

What does a Cyclically Adjusted Book per Share of NT$32.10 mean?
Tanvex BioPharma (TPE:6541) has a Cyclically Adjusted Book per Share of NT$32.10 as of Dec. 2025. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Tanvex BioPharma and its competitors.
Is Tanvex BioPharma's Cyclically Adjusted Book per Share too high?
Tanvex BioPharma's current Cyclically Adjusted Book per Share is NT$32.10. Overall, Tanvex BioPharma has a GF Score™ of 57/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Tanvex BioPharma's Cyclically Adjusted Book per Share compare to VRTX and REGN?
Tanvex BioPharma's Cyclically Adjusted Book per Share of NT$32.10 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Book per Share for a Biotechnology company?
A good Cyclically Adjusted Book per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Book per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Book per Share mean?
A high Cyclically Adjusted Book per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Tanvex BioPharma and its competitors. Tanvex BioPharma's current Cyclically Adjusted Book per Share is NT$32.10. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tanvex BioPharma stock overvalued right now?
Based on GuruFocus' analysis, Tanvex BioPharma (TPE:6541) is currently considered Possible Value Trap. The stock's GF Value™ is NT$254.61, compared to a current price of NT$41.40 — trading 83.7% below its estimated fair value. The current Cyclically Adjusted Book per Share is NT$32.10. Tanvex BioPharma's overall GF Score™ is 57/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Book per Share calculated?
Cyclically Adjusted Book per Share is calculated from a company's financial statements. For Tanvex BioPharma (TPE:6541), the current Cyclically Adjusted Book per Share is NT$32.10 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Tanvex BioPharma (TPE:6541) Overvalued in 2026?

Based on GuruFocus' analysis, Tanvex BioPharma stock appears to be undervalued. The current stock price of NT$41.40 is trading 83.7% below its estimated GF Value™ of NT$254.61. GuruFocus considers Tanvex BioPharma to be Possible Value Trap.

Key valuation signals for TPE:6541:

  • Cyclically Adjusted Book per Share: NT$32.10
  • GF Value™: NT$254.61 vs. price of NT$41.40 (83.7% below fair value)
  • GF Score™: 57/100 with 4 warning signs

No single metric tells the full story. See the TPE:6541 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Tanvex BioPharma Business Description

Address No. 12-2, Shengyi Road, Section 2, 6th Floor, Hsinchu County, Zhubei, TWN, 106
Tanvex BioPharma Inc is a biopharmaceutical company. It is engaged in the research, development, manufacture, and sale of biosimilar products and contract development and manufacturing of biological medicine. The company's products are used to cure diseases such as Neutropenia, Breast Cancer, Metastatic Colorectal Cancer, and others. Geographically, the company operates in Asia, America, Europe, and Australia. The company generates a majority of its revenue from the USA.
57GF Score

Get the complete analysis for TPE:6541

Cyclically Adjusted Book per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$41.40
Price
NT$254.61
GF Value